KZA Media Thread, page-34

Here maybe this will help you.

"James Minow, Executive Director of Cure JM said: “Andrew has exceptional experience and a strong track record of innovation in the fields of biotech, drug development and business development. His dedication to finding treatments to rare and life-threatening diseases and compassion for patients and families make him the ideal choice to lead our research program to the next level of achievement.”"

As for cantrixil it is best summed up by Dr Kelly some one you respect

"Phenoxodiol is to TRXE-002 (the active ingredient in Cantrixil) what an electric car is to a F1 racing car.
The IC50 frange or phenoxodiol is 2000-5000 nM. The range for TRXE-002 is 10-100 nM.
Phenoxodiol has no effect on cancer stem cells; TRXE-002 is highly potent against cancer stem cells
.Phenoxodiol is a potent chemo-sensitiser; TRXE-002 has no chemo-sensitising ability.
Phenoxodiol is an interesting drug; TRXE-002 is a potential breakthrough drug."

Correct again I am not shy.

Nice use of a logic tautology though. But repeating a presupposition in two differents ways to try and force a point is piss poor way of trying to score a cheap shot.